F S&P 500
5,251.25 +5.00 (+0.10%) F Dow Jones
39,657.00 +15.00 (+0.04%) F Nasdaq
18,285.75 +30.75 (+0.17%) E-mini Russell 2000 Index Futur
2,073.90 +6.00 (+0.29%) Petróleo
78.41 +0.15 (+0.19%) Oro
2,353.20 -21.80 (-0.92%)
Unity Biotechnology, Inc. (UBX)
Fuera de horario:
Unity Biotechnology, Inc.
285 East Grand Avenue
South San Francisco, CA 94080
United States
650 416 1192
https://unitybiotechnology.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 19
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Anirvan Ghosh Ph.D. | CEO & Director | 940.4k | N/D | 1964 |
| Dr. Nathaniel E. David A.B., Ph.D. | Co-Founder & Executive Director | 40k | N/D | 1968 |
| Ms. Lynne Marie Sullivan | CFO & Head of Corporate Development | 663.63k | N/D | 1966 |
| Mr. Alexander Hieu Nguyen J.D. | Chief Legal Officer, Head of Operations & Corporate Secretary | 589.4k | N/D | 1977 |
| Dr. Jan M. van Deursen | Founder | N/D | N/D | N/D |
| Dr. Judith Campisi Ph.D. | Founder | N/D | N/D | N/D |
| Mr. Daohong Zhou M.D. | Founder | N/D | N/D | N/D |
| Dr. Przemyslaw Sapieha Ph.D. | Chief Scientist | N/D | N/D | N/D |
| Ms. Sharon Klier M.D., M.P.H. | Head of Ophthalmology & Chief Development Officer | N/D | N/D | N/D |
Descripción
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Unity Biotechnology, Inc. a partir del 1 de mayo de 2024 es 10. Las puntuaciones principales son Auditoría: 9; Junta: 9; Derechos del accionista: 8; Compensación: 10.
